A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

BACKGROUND: While the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of choice when this trial commenced. This study intended to provide supportive ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansiime, Freddie, Adibaku, Seraphine, Wamboga, Charles, Idi, Franklin, Kato, Charles Drago, Yamuah, Lawrence, Vaillant, Michel, Kioy, Deborah, Olliaro, Piero, Matovu, Enock
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824494/
https://www.ncbi.nlm.nih.gov/pubmed/29471865
http://dx.doi.org/10.1186/s13071-018-2634-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824494/
https://www.ncbi.nlm.nih.gov/pubmed/29471865
http://dx.doi.org/10.1186/s13071-018-2634-x

Ejemplares similares